Cargando…

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer

OBJECTIVE: Several pathways are known to be activated during metastasis and treatment of cancer. We investigated the role of osteopontin (OPN) and stathmin-1 (STHMN1) in metastatic castrate-resistant (mCRPC). METHODS: We included 30 patients who received at least 6 cycles of taxane regimen for metas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aksoy, Asude, Artas, Gokhan, Sevindik, Omur Gokmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510103/ https://www.ncbi.nlm.nih.gov/pubmed/28811771 http://dx.doi.org/10.12669/pjms.333.12559

Ejemplares similares

siRNA-mediated stathmin1 silencing inhibits proliferation of prostate carcinoma cell line
por: AKSOY, Asude, et al.
Publicado: (2022)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma
por: Aksoy, Asude, et al.
Publicado: (2023)

Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves
por: Marano, Francesca, et al.
Publicado: (2016)

Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
por: Sarwar, Sadia, et al.
Publicado: (2022)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study
por: Dayyani, Farshid, et al.
Publicado: (2016)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells
por: Eskra, Jillian N., et al.
Publicado: (2019)

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane
por: Hassan, Mohamed Kamel, et al.
Publicado: (2015)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
por: Moreira, Daniel M., et al.
Publicado: (2015)

Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients
por: Pölsterl, Sebastian, et al.
Publicado: (2017)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
por: Huang, Phoebe A., et al.
Publicado: (2018)

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_se4e9ap7auqg01jb5h6q08kpil